Literature DB >> 33603670

Involvement of Circulating Exosomal MicroRNAs in Jian-Pi-Yi-Shen Formula Protection Against Adenine-Induced Chronic Kidney Disease.

Xinhui Liu1, Siqi Liu1, Denggui Luo1, Shiying Huang2, Fochang Wang2, Bing Zhang1, Yulian Chen1, Lin Zheng2, Jiandong Lu1, Shunmin Li1.   

Abstract

Jian-Pi-Yi-Shen formula (JPYSF) is a traditional Chinese medicine (TCM) formula used in clinic to treat chronic kidney disease (CKD) for decades. However, the mechanisms of JPYSF in treating CKD have not been fully elucidated. The aim of the present study was to test the renoprotective effect of JPYSF on CKD rat model and investigate the potential mechanism from the perspective of serum exosomal microRNAs (miRNAs). CKD rat model was induced by feeding Sprague-Dawley rats a diet containing 0.75% w/w adenine for four weeks. The rats in the treatment group were given 10.89 g/kg JPYSF by gavage every day, starting from the 3rd week of the adenine-containing diet for six weeks. Serum biochemistry and histopathology were used to evaluate the renoprotective effects of JPYSF. Serum exosomes were isolated by ExoQuick-TC PLUS exosomes extraction kit and were identified by transmission electron microscopy, nanoparticle tracking analysis, and western blot. Exosomal miRNAs profiling was analyzed by small RNA sequencing. The results showed that JPYSF treatment significantly lowered serum creatinine and blood urea nitrogen levels and alleviated renal pathological injury in CKD rats. Furthermore, serum exosomes were successfully isolated and identified. Small RNA sequencing revealed that 4 exosomal miRNAs (miR-192-5p, miR-194-5p, miR-802-5p, and miR-143-3p) were significantly downregulated in the CKD group and were markedly upregulated after JPYSF treatment. At last, miR-192-5p was identified as the most relevant miRNA for CKD diagnosis and JPYSF treatment. In conclusion, JPYSF protects kidney from adenine-induced CKD, which may be associated with modulation of exosomal miRNAs.
Copyright © 2021 Liu, Liu, Luo, Huang, Wang, Zhang, Chen, Zheng, Lu and Li.

Entities:  

Keywords:  Jian-Pi-Yi-Shen formula; chronic kidney disease; exosomal microRNAs; small RNA sequencing; traditional Chinese medicine

Year:  2021        PMID: 33603670      PMCID: PMC7884821          DOI: 10.3389/fphar.2020.622658

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  41 in total

1.  Serum miR-192 Is Related to Tubulointerstitial Lesion and Short-Term Disease Progression in IgA Nephropathy.

Authors:  Qichen Fan; Renhua Lu; Mingli Zhu; Yucheng Yan; Xiangjiang Guo; Yingying Qian; Lulu Zhang; Huili Dai; Zhaohui Ni; Leyi Gu
Journal:  Nephron       Date:  2019-02-26       Impact factor: 2.847

2.  miR-192 mediates TGF-beta/Smad3-driven renal fibrosis.

Authors:  Arthur C K Chung; Xiao R Huang; Xiaoming Meng; Hui Y Lan
Journal:  J Am Soc Nephrol       Date:  2010-05-20       Impact factor: 10.121

3.  miR-192 prevents renal tubulointerstitial fibrosis in diabetic nephropathy by targeting Egr1.

Authors:  F Liu; Z-P Zhang; G-D Xin; L-H Guo; Q Jiang; Z-X Wang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-07       Impact factor: 3.507

4.  MicroRNA-29c in urinary exosome/microvesicle as a biomarker of renal fibrosis.

Authors:  Lin-Li Lv; Yu-Han Cao; Hai-Feng Ni; Min Xu; Dan Liu; Hong Liu; Ping-Sheng Chen; Bi-Cheng Liu
Journal:  Am J Physiol Renal Physiol       Date:  2013-08-14

5.  MiR-192-5p in the Kidney Protects Against the Development of Hypertension.

Authors:  Maria Angeles Baker; Feng Wang; Yong Liu; Alison J Kriegel; Aron M Geurts; Kristie Usa; Hong Xue; Dandan Wang; Yiwei Kong; Mingyu Liang
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

6.  Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease.

Authors:  Rimpi Khurana; Glory Ranches; Simon Schafferer; Melanie Lukasser; Michael Rudnicki; Gert Mayer; Alexander Hüttenhofer
Journal:  RNA       Date:  2016-11-21       Impact factor: 4.942

Review 7.  Extracellular Vesicles in Renal Pathophysiology.

Authors:  Margherita A C Pomatto; Chiara Gai; Benedetta Bussolati; Giovanni Camussi
Journal:  Front Mol Biosci       Date:  2017-06-07

Review 8.  New insight into the role of extracellular vesicles in kidney disease.

Authors:  Lin-Li Lv; Ye Feng; Tao-Tao Tang; Bi-Cheng Liu
Journal:  J Cell Mol Med       Date:  2018-12-25       Impact factor: 5.310

9.  MiR-21 is up-regulated in urinary exosomes of chronic kidney disease patients and after glomerular injury.

Authors:  Tim Lange; Nadine Artelt; Frances Kindt; Sylvia Stracke; Rainer Rettig; Uwe Lendeckel; Christos E Chadjichristos; Panagiotis Kavvadas; Christos Chatziantoniou; Karlhans Endlich; Nicole Endlich
Journal:  J Cell Mol Med       Date:  2019-05-07       Impact factor: 5.310

10.  MicroRNAs contribute to the maintenance of cell-type-specific physiological characteristics: miR-192 targets Na+/K+-ATPase β1.

Authors:  Domagoj Mladinov; Yong Liu; David L Mattson; Mingyu Liang
Journal:  Nucleic Acids Res       Date:  2012-12-05       Impact factor: 16.971

View more
  4 in total

1.  Jian-Pi-Yi-Shen Formula Improves Adenine-Induced Chronic Kidney Disease via Regulating Tryptophan Metabolism and Aryl Hydrocarbon Receptor Signaling.

Authors:  Xinhui Liu; Ruyu Deng; Yulian Chen; Shiying Huang; Jiandong Lu; Lin Zheng; Guoliang Xiong; Shunmin Li
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

2.  Identification of cell cycle as the critical pathway modulated by exosome-derived microRNAs in gallbladder carcinoma.

Authors:  Li Su; Jicheng Zhang; Xinglong Zhang; Lei Zheng; Zhifa Zhu
Journal:  Med Oncol       Date:  2021-10-16       Impact factor: 3.064

Review 3.  Exosomes: A novel insight into traditional Chinese medicine.

Authors:  Chao Mo; Jie Zhao; Jingyan Liang; Huiling Wang; Yu Chen; Guodong Huang
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

Review 4.  What do we actually know about exosomal microRNAs in kidney diseases?

Authors:  Qianyu Li; Zhiping Zhang; Min Yin; Cancan Cui; Yucheng Zhang; Yali Wang; Feng Liu
Journal:  Front Physiol       Date:  2022-08-29       Impact factor: 4.755

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.